Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Official title

Multi-cohort, Open, Phase II Clinical Study of TQB2868 Injection Combined With Arotinib Capsule and Chemotherapy in the First-line Treatment of Pancreatic Neoplasms

Overview

To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms

Interventions

• Drug TQB2868 injection
  TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.
• Drug Gemcitabine injection
  Gemcitabine injection
• Drug Albumin paclitaxel injection
  Albumin paclitaxel injection
• Drug Anlotinib capsules
  Anlotinib capsules

Primary outcome measures

• Progression-free survival (PFS) [Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)]

Secondary outcome measures (12)

• Objective Response Rate (ORR) [Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)]
• Overall survival (OS) [Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)]
• Duration of Response (DOR) [Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)]
• Disease Control Rate (DCR) [Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)]
• Incidence and severity of adverse events (AEs) [Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)]
• Peak concentration (Cmax) [Time frame: Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.]
• Transforming growth factor-beta (TGF-β) [Time frame: Before first dose, 30 minutes after the first dose, pre-dose at Cycle 2 Day 1, pre-dose at the first efficacy assessment, pre-dose at the time of remission at the first efficacy evaluation, and at the time of progression, each cycle is 28 days.]
• Incidence of immunogenicity (ADA) [Time frame: Cycle1, 2, 4, 8: Before injection. 30 and 90 days after the last dose]
• Time to maximum blood concentration (Tmax) [Time frame: Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.]
• Area under the time-concentration curve (AUC0-t） [Time frame: Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.]
• The area under the time-concentration curve ranges from 0 to infinity after administration (AUC0-∞) [Time frame: Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.]
• Plasma drug half-life (T1/2) [Time frame: Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.]

Eligibility criteria

Inclusion criteria

• Subjects must voluntarily participate in the study and sign the informed consent form.
• Aged between 18 and 75 years (inclusive) at the time of signing the informed consent form.
• Diagnosed with pancreatic ductal adenocarcinoma through histological or cytological confirmation.
• Have at least one evaluable metastatic lesion according to RECIST 1.1 criteria;
• No prior systemic anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, targeted therapy, or immunotherapy). Patients who experience disease progression more than 6 months after completing neoadjuvant or adjuvant therapy are eligible.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, with an expected survival of more than 3 months.
• Normal major organ function.
• Patients must use reliable contraception during the study period and for 6 months after the end of the study period; Female participants must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.

Exclusion criteria

• Subjects with a history of or concurrent diagnosis of other malignant tumors within the past 5 years.
• Unresolved toxicities from prior treatments exceeding Grade 1 according to Common Terminology Criteria (CTC) AE criteria, excluding alopecia.
• Major surgical procedures, significant traumatic injuries, or unhealed wounds or fractures within 28 days prior to the first dose.
• Any bleeding or hemorrhagic event of ≥ Grade 3 according to CTC AE criteria within 4 weeks prior to the first dose.
• Arterial or venous thrombotic events within 6 months prior to the first dose.
• Active gastric or duodenal ulcers, perforations, persistent positive fecal occult blood tests, ulcerative colitis, or other gastrointestinal bleeding conditions within 6 months prior to the first dose; or other bleeding conditions as assessed by the investigator.
• Hepatitis B virus (HBV)-infected patients unable to adhere to consistent antiviral therapy, or Hepatitis C virus (HCV)-infected patients (positive for HCV Ab or HCV RNA) deemed unstable by the investigator or requiring continued antiviral therapy without consistent adherence.
• History of substance abuse involving psychotropic drugs that cannot be discontinued or presence of psychiatric disorders.
• Symptomatic interstitial lung disease or conditions likely to cause drug-induced lung toxicity or related pneumonitis.
• Presence of any severe and/or uncontrolled diseases.
• Histological or cytological confirmation of other pathological types, such as acinar cell carcinoma, neuroendocrine carcinoma, or pancreatoblastoma.
• Tumors confirmed via imaging (CT or MRI) to have invaded major blood vessels, with the investigator deeming a high likelihood of fatal hemorrhage during the study.
• Tumors confirmed via imaging (CT or MRI) to have invaded the gastrointestinal tract, with a high risk of bleeding based on endoscopy and investigator assessment.
• Known central nervous system metastases and/or carcinomatous meningitis.
• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage, as assessed by the investigator.
• History of severe allergic reactions to biologic agents or known hypersensitivity to any component of TQB2868 injection.
• Chronic treatment with systemic corticosteroids or other immunosuppressive agents within 28 days prior to the first dose, and continued use of such medications within 2 weeks after the first dose.
• Receipt of live attenuated vaccines within 28 days prior to the first dose or planned administration of live attenuated vaccines during the study.
• Systemic therapy required within 2 years prior to the first dose for any condition. Alternative therapies are not considered systemic therapy.
• Participation in other clinical trials involving anti-tumor drugs within 28 days prior to the first dose.
• Any comorbidities or conditions deemed by the investigator to pose severe risks to the subject's safety or the completion of the study, or any other reasons rendering the subject unsuitable for enrollment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 7 centers

• Henan Cancer Hospital — Zhengzhou
• The Second Affiliated Hospital of Zhengzhou University — Zhengzhou
• Jiangsu Provincial People's Hospital — Nanjing
• Nanjing Drum Tower Hospital — Nanjing
• The First Affiliated Hospital of Soochow University — Suzhou
• Fudan University Shanghai Cancer Center — Shanghai
• The First Affiliated Hospital of Wenzhou Medical University — Wenzhou

Identifiers

NCT: NCT06767813 · TQB2868-ALTN-II-01

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗